UBXN4: The UBXN4 Protein and Its Potential as a Drug Target or Biomarker

Target Name: UBXN4

NCBI ID: G23190

UBXN4

UBXN4: The UBXN4 Protein and Its Potential as a Drug Target or Biomarker

The UBXN4 protein is a member of the UBX gene family, which is known for its role in the development and maintenance of nervous system structure and function. The UBXN4 gene has four splice variants, which result in the production of different isoforms of the UBXN4 protein. The most abundant is the UBXN4-long isoform, which consists of 215 amino acids and is expressed in the brain and spinal cord. The other isoforms, which are shorter in length, have different functions in various physiological processes.

The UBXN4 protein is involved in the regulation of neuronal excitability and in the development of neurodegenerative diseases. It has been implicated in a number of neurological disorders, including Alzheimer's disease, Parkinson's disease, and neurofibrillary tangles in Alzheimer's disease.

UBXN4 as a Drug Target

The UBXN4 protein is a potential drug target because of its involvement in the development and progression of neurodegenerative diseases. Drugs that target the UBXN4 protein have been shown to improve cognitive function in animal models of Alzheimer's disease and to reduce the formation of neurofibrillary tangles in the brain.

One class of drugs that have been shown to target the UBXN4 protein is the RNA-based therapeutics. These drugs work by modulating the expression of specific genes, including UBXN4. One such drug is currently in clinical trials for the treatment of Alzheimer's disease.

Another class of drugs that have been shown to target the UBXN4 protein are the small molecules that have been shown to modulate the activity of the UBXN4 protein. These drugs work by binding to specific residues on the UBXN4 protein and modulating its activity.

UBXN4 as a Biomarker

The UBXN4 protein is also a potential biomarker for the diagnosis and progression of neurodegenerative diseases. The UBXN4 protein is expressed in the brain and has been shown to be abnormally expressed in the brains of individuals with Alzheimer's disease and other neurodegenerative disorders.

Research has also shown that the UBXN4 protein is involved in the development of neurofibrillary tangles in the brain, which are a hallmark of neurodegenerative diseases. The presence of neurofibrillary tangles in the brain can be used as a diagnostic indicator of the severity of a neurodegenerative disorder.

The UBXN4 protein is also involved in the regulation of neuronal excitability, which is an important aspect of the development and progression of neurodegenerative diseases. Abnormalities in neuronal excitability have been implicated in the development of various neurodegenerative disorders, including Alzheimer's disease.

Conclusion

The UBXN4 protein is a member of the UBX gene family that is involved in the regulation of neuronal excitability and the development and progression of neurodegenerative diseases. The UBXN4 protein is a potential drug target and biomarker for the diagnosis and treatment of these disorders. Further research is needed to fully understand the role of the UBXN4 protein in the development and progression of neurodegenerative diseases.

Protein Name: UBX Domain Protein 4

Functions: Involved in endoplasmic reticulum-associated protein degradation (ERAD). Acts as a platform to recruit both UBQLN1 and VCP to the ER during ERAD (PubMed:19822669)

The "UBXN4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBXN4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets